A class of medicines you've almost certainly heard of, Ozempic, Wegovy, Mounjaro, Zepbound, has built one of the biggest investing stories of the decade. The market is racing toward an estimated $200 billion, one maker briefly became the first healthcare company ever worth $1 trillion, and the ripple effects are rewriting the outlook for everything from snack makers to gyms.
And yet here's the twist that makes it such a valuable lesson: the company that invented the entire category saw its shares fall around 40% over three years, even as the market boomed. A world-changing product. A gigantic, growing market. And still, being first guaranteed nothing.
That paradox is what makes the "GLP-1 economy" one of the richest case studies in investing today. This guide explains how it works as a theme: the enormous market, the fierce two-horse race at its centre, the way the Covid windfall gave way to this as pharma's next big driver, the surprising knock-on effects on food, fitness and medical-device companies, and, crucially, the honest risks. If it leaves you wanting to explore listed healthcare and consumer stocks, you can do that from just $1 with zero commission on the Nemo.money app.
What Are GLP-1 Drugs, and Why Do Markets Care?
GLP-1 receptor agonists are a class of drugs that help regulate blood sugar and appetite. First used to treat type-2 diabetes, they turned out to produce significant weight loss, and that discovery opened up a vast new market. For investors, the appeal is simple to state:
- Obesity and diabetes are enormous, global, growing markets. Hundreds of millions of people are potentially addressable, across both rich and developing countries.
- The drugs work well enough to drive huge demand. That's translated into some of the fastest product launches in pharmaceutical history.
- The runway looks long. New formulations (especially pills), new uses, and expanding insurance coverage could keep the market growing for years.
Estimates vary, but the scale is striking: JPMorgan projects the broader "incretin" market (which includes GLP-1s) could reach around $200 billion by 2030, with roughly 25 million Americans on treatment by then, up from about 5 million in 2023. Morgan Stanley sees the obesity-and-diabetes drug market hitting roughly $190 billion by 2035. Different methodologies produce different numbers, but they all point the same way: very big, and growing fast.
The Main Event: A Fierce Two-Horse Race
At the centre of the theme sit two pharmaceutical giants locked in one of the most consequential rivalries in business:
- Eli Lilly (NYSE: LLY) is currently the front-runner, thanks to its tirzepatide drugs (Mounjaro for diabetes, Zepbound for weight loss). Zepbound has become the best-selling anti-obesity drug, and Lilly has held roughly 60% of the US GLP-1 obesity market in early 2026. In 2026 Lilly briefly became the first healthcare company ever valued at $1 trillion.
- Novo Nordisk (NYSE: NVO), the Danish company that started it all with semaglutide (Ozempic for diabetes, Wegovy for weight loss), was the original leader but lost ground to Lilly, prompting a new CEO, job cuts and a fightback.
The current battleground is pills. Injections defined the first wave; oral versions are defining the next. Novo launched an oral Wegovy pill in early 2026 that became one of the fastest pharmaceutical launches on record, surpassing 3 million prescriptions within about five months, while Lilly rolled out its own oral competitor. Importantly, around two-thirds of new pill users are people new to GLP-1s altogether, which suggests pills are expanding the overall market rather than just cannibalising injections.
The New Entrants: The Race Is Getting Crowded
The size of the prize has drawn a crowd, which is great for competition but a warning sign for anyone assuming today's leaders stay on top:
- Pfizer (NYSE: PFE) bought its way in, acquiring obesity-drug developer Metsera for up to around $10 billion in 2025, and is targeting a first approval later this decade.
- Chinese innovators (such as Innovent, Hengrui and others) are advancing their own obesity drugs, both at home and, increasingly, with global ambitions, and Western firms like AstraZeneca have struck deals to access Chinese pipelines.
- A wave of next-generation candidates (combination therapies, monthly injections, triple-acting drugs) is coming, any of which could reshuffle the leaderboard.
The "After Covid" Angle: Pharma's Hunt for the Next Blockbuster
There's a bigger industry backdrop that helps explain why GLP-1s have gripped investors so completely. For a couple of years, the pandemic gave big pharma an extraordinary, one-off windfall, Pfizer's revenue rocketed to around $100 billion in 2022 at the peak of Covid-vaccine and antiviral demand. Then it faded fast: Comirnaty and Paxlovid sales fell sharply as the emergency passed, and Pfizer's revenue dropped back to roughly $60 billion, with Covid products now a small fraction of the total.
That left the industry with a familiar question: what's the next big growth engine? For Eli Lilly and Novo Nordisk, the answer became GLP-1s, arguably the first blockbuster class of comparable financial scale to emerge since the Covid windfall. And for companies that rode the pandemic wave and are now watching it recede, obesity has become a prime target to pivot into: Pfizer, for instance, has leaned into oncology and made a roughly $10 billion move into obesity drugs (buying Metsera) explicitly to help offset declining Covid revenue.
For investors, this is the real "after Covid" story in pharma, not that GLP-1s are a pandemic, but that they've become the industry's next major growth theme as the Covid boom fades. It's a useful reminder, though, that pharma runs in waves: the Covid windfall was huge and temporary, and even blockbuster franchises eventually face competition, pricing pressure and patent expiry (which is exactly why the risks below matter).
The Ripple Effects: Where It Gets Really Interesting
Here's what makes the GLP-1 story bigger than just two drug stocks. If hundreds of millions of people eat less, that reshapes other industries, and investors have been repricing companies accordingly:
- Food & beverage: This is the headline ripple. JPMorgan has estimated GLP-1 users consume around 21% fewer calories, and that the trend could cut food-and-beverage industry revenue by roughly $30-55 billion a year by 2030-2034. That has pressured sentiment around snack, confectionery and fast-food companies, though many are adapting with smaller portions and high-protein products.
- Medical devices: A double-edged sword. Makers of diabetes-management and sleep-apnea devices could see changing demand, while others may benefit as healthier patients live longer.
- Fitness, apparel and "after GLP-1" categories: Everything from gyms to clothing to cosmetic procedures is being re-examined for knock-on effects, positive and negative.
The investing lesson here is elegant: a single medical breakthrough can ripple across food, retail, devices and beyond. Spotting second-order effects is a core part of thematic investing, but, as we'll see, spotting them is not the same as profiting from them.
The Honest Risks (Please Read This Part)
This is the essential counterweight, because the GLP-1 theme has been a genuinely humbling one for investors. A powerful story has not meant a smooth ride:
- A great theme hasn't meant a great stock. The clearest example: Novo Nordisk, the pioneer of the entire category, saw its shares fall roughly 40% over three years even as the theme boomed, as competition and pricing pressure bit. Being early to a huge trend guaranteed nothing.
- Pricing pressure is intense. US prices have been cut sharply (cash prices for some treatments dropping toward a few hundred dollars a month), which is great for patients but squeezes company margins.
- Patents expire. Blockbuster drugs eventually face generic competition, and some key patents (for example in certain markets) are already lapsing, threatening future revenue.
- Competition can crush margins. With Pfizer, Chinese firms and others piling in, today's dominant players could see pricing and share eroded.
- Execution and science risk. Trials can disappoint (some next-generation candidates have missed targets), launches can stumble, and supply chains have struggled to keep up.
- A theme is not a stock. "GLP-1s will be huge" can be entirely true while any individual company, even a leader, disappoints. Some investors prefer diversified healthcare funds precisely to avoid betting on one winner, though that never removes risk.
How to Explore Healthcare & Consumer Stocks with Nemo.money
If the GLP-1 theme interests you, the Nemo.money app lets you explore the listed players across pharma and the sectors it touches:
- Invest from Just $1: Fractional shares let you start small with eligible stocks and ETFs.
- Zero-Commission Trading: Buy and sell eligible US-market stocks and ETFs without commission fees.
- AI-Powered Insights & Nemes: Explore curated, themed stock collections (Nemes), with real-time data and sentiment.
- Earn on Idle Cash: Earn 6% AER interest, paid daily in USD, on uninvested cash in your wallet.
Frequently Asked Questions (FAQs)
What are GLP-1 drugs?
GLP-1 receptor agonists are a class of medicines that help regulate blood sugar and appetite. Originally developed for type-2 diabetes, they also produce significant weight loss, which created a large new market. Well-known examples include Ozempic and Wegovy (Novo Nordisk) and Mounjaro and Zepbound (Eli Lilly). This is general information about the investing theme, not medical advice.
Which companies make weight-loss drugs?
The two leaders are Eli Lilly (NYSE: LLY), maker of Mounjaro and Zepbound, and Novo Nordisk (NYSE: NVO), maker of Ozempic and Wegovy. Newer entrants include Pfizer (NYSE: PFE), which acquired obesity-drug developer Metsera, along with several Chinese drugmakers and others developing next-generation treatments. All named as examples to research, not recommendations, and your capital is at risk.
How big is the weight-loss drug market?
Very large and growing. Estimates vary by methodology, but JPMorgan projects the broader incretin market (including GLP-1s) could reach around $200 billion by 2030, while Morgan Stanley estimates the obesity-and-diabetes drug market could hit roughly $190 billion by 2035. Different forecasts give different figures, but all point to strong, sustained growth.
How do weight-loss drugs affect food and other companies?
Because GLP-1 users tend to eat less (JPMorgan estimates around 21% fewer calories), analysts expect knock-on effects across food and beverage (with estimates of tens of billions in reduced annual revenue by the early 2030s), plus mixed effects on medical devices, fitness and other consumer categories. Many food companies are adapting with smaller portions and higher-protein products. These are second-order effects investors watch, not guarantees.
Are weight-loss drug stocks a good investment?
There's no simple answer. The long-term theme is powerful, but the stocks have been volatile: Novo Nordisk, the category pioneer, fell around 40% over three years even as the market grew, hit by competition and pricing pressure. Pricing cuts, patent expiries, intense competition and trial setbacks are all real risks. A strong theme doesn't guarantee any single stock succeeds.
Final Thoughts: A Genuine Revolution, but Not a Free Lunch
The GLP-1 story is one of the most significant in modern healthcare, and one of the richest case studies in thematic investing. It shows how a single breakthrough can create a multi-hundred-billion-dollar market and ripple outward into food, fitness and beyond. But it's also a masterclass in why a brilliant theme is not the same as a brilliant investment: the very company that pioneered it lost around 40% of its value even as the theme took off.
Understand the business, respect the risks, remember it's a fast-moving and competitive field, and treat it as a long-term area to research rather than a sure thing. If it interests you, you can explore listed healthcare and consumer stocks from $1 with zero commission on the Nemo.money app.
Nemo = Never Miss Out.
Stay informed. Stay ahead.
#GLP1 #Ozempic #Investing #Healthcare #Pharma #NemoMoney
This is not investment advice, and it is not medical advice. Past performance is not indicative of future results. Your capital is at risk. See website for Risk Disclosure. Exinity ME Ltd (https://nemo.money) is regulated by ADGM's Financial Services Regulatory Authority.
